Oncoquest-CLL (ATCE vaccine)
/ R2T Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 23, 2021
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
(clinicaltrials.gov)
- P1; N=30; Active, not recruiting; Sponsor: XEME Biopharma Inc.; Trial completion date: Jan 2022 ➔ Jan 2024; Trial primary completion date: Jan 2021 ➔ Jan 2024
Clinical • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology
January 11, 2019
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
(clinicaltrials.gov)
- P1; N=30; Active, not recruiting; Sponsor: XEME Biopharma Inc.; Trial completion date: Dec 2017 ➔ Jan 2022; Trial primary completion date: Dec 2017 ➔ Jan 2021
Clinical • Trial completion date • Trial primary completion date
1 to 2
Of
2
Go to page
1